| Pharmaceutical Information |
| Drug Name |
Pralatrexate |
| Drug ID |
BADD_D01814 |
| Description |
Pralatrexate is an antimetabolite for the treatment of relapsed or refractory peripheral T-cell lymphoma. It is more efficiently retained in cancer cells than methotrexate. FDA approved on September 24, 2009. |
| Indications and Usage |
Treatment of relapsed or refractory peripheral T-cell lymphoma. |
| Marketing Status |
Prescription |
| ATC Code |
L01BA05 |
| DrugBank ID |
DB06813
|
| KEGG ID |
D05589
|
| MeSH ID |
C418863
|
| PubChem ID |
148121
|
| TTD Drug ID |
D02LWU
|
| NDC Product Code |
72893-003; 48818-001; 47848-045; 68554-0071; 53183-4020; 72893-005; 65392-2510 |
| Synonyms |
10-propargyl-10-deazaaminopterin | pralatrexate |
|
| Chemical Information |
| Molecular Formula |
C23H23N7O5 |
| CAS Registry Number |
146464-95-1 |
| SMILES |
C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
